Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Endo Chief Has $500 Million for Cancer, Urology Deals

Don't Miss Out —
Follow us on:

Jan. 12 (Bloomberg) -- Endo Pharmaceuticals Holdings Inc. has a $500 million budget for acquisitions and is seeking health information technology and diagnostic tools for cancer and urology, Chief Executive Officer David Holveck said.

“Everything in the treatment of patients starts with diagnostics,” Holveck said today in an interview at the J.P. Morgan Healthcare Conference in San Francisco. “A lot of the earlier diagnostics didn’t have access to what we know today as molecular diagnostics that are much more specific.”

The Chadds Ford, Pennsylvania-based maker of tamper-proof pain pills has announced completion of six deals in the past five years, with an average size of $352.8 million and a typical premium of 49 percent, according to data compiled by Bloomberg.

Endo’s shares rose their highest value in three years on Sept. 28 after the company agreed to buy U.S. generic-drugmaker Qualitest Pharmaceuticals for about $1.2 billion from private-equity firm Apax Partners LLP. In May, the company said it would Acquire HealthTronics Inc., a provider of urologic lab services and devices, for $223 million.

Endo fell 5 cents, or less than a percent, to $34.10 at 4 p.m. New York time in Nasdaq Stock Market composite trading. The shares gained 73 percent in the past 12 months.

To contact the reporter on this story: Sasha Damouni in New York at sdamouni2@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.